024 Asymmetric cell division for fate induction of chimeric antigen receptor (CAR) T cells

نویسندگان

چکیده

Early expansion and long-term persistence predict efficacy of genetically-engineered T cells. While this is thought to reflect induction effector memory cell populations provide both short-term clearance long-lasting remission, the cellular mechanisms fate after activation through synthetic receptors are unknown. A better understanding such processes could improve therapeutic outcome. Here we show that human cells engineered express chimeric antigen (CARs) undergo asymmetric division (ACD) with distinct proximal distal daughter adopt phenotypes, respectively. Using molecular proximity labeling distinguish first cells, demonstrate target-engaged CAR molecules remain on establish asymmetry between in proliferative pace, cytolytic function metabolic program. The single transcriptional program driven by c-myc, mTORC1 JAK-STAT3 (each adjusted p<0.001) resulting predominance glycolytic metabolism, features consistent differentiation. Conversely, utilize BACH-2, ETS-2 KLF2 shape their transcriptome rely oxidative phosphorylation, indicating a precursor phenotype. In vivo characterization two xenograft leukemia mouse models evaluate confirms superior elimination (n=14, p=0.0004) (n=12, p=0.0051) establishing these as precursors responsible for Collectively, studies uncover ACD novel framework differentiation influencing outcomes.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Surgery, chemotherapy, and radiation therapy have been the foundation of cancer treatment. Advances in the field of immunology (a branch of science that studies all aspects of the immune system) have led to a greater understanding of the ways in which the body’s own defenses can be used for treatment of blood cancers. Cancer researchers are now studying how the immune system can help destroy ca...

متن کامل

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities

Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for solid tumors currently is faced with numerous challenges such as physical barriers, the immunosuppr...

متن کامل

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Antibodiesblocking theprogrammeddeath1 receptor (PD-1) onTcells produce tumor regression in multiple cancers by disrupting the PD-L1/ PD-1 (programmed death-ligand 1/programmed cell death protein 1) immune inhibitory axis. This approach to cancer immunotherapy would seem to be an ideal partner for chimeric antigen receptor (CAR)– modified T-cell therapies but is, as yet, untested in this settin...

متن کامل

Advancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects

Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs ...

متن کامل

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy

Chimeric Antigen Receptor (CAR) T-cells are T-cells with recombinant receptors targeted to tumor antigens. CAR-T cell therapy has emerged as a mode of immunotherapy and is now being extensively explored in hematologic cancer. In contrast, CAR-T cell use in solid tumors has been hampered by multiple obstacles. Several approaches have been taken to circumvent these obstacles, including the region...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Investigative Dermatology

سال: 2022

ISSN: ['1523-1747', '0022-202X']

DOI: https://doi.org/10.1016/j.jid.2022.05.078